## Pathophysiology of Uterine Fibroids **Key Point:** Uterine fibroids (leiomyomas) are benign smooth muscle tumors with NO malignant potential. The statement claiming a 15-20% risk of malignant transformation is FALSE and is the correct answer to this "EXCEPT" question. ### True Statements About Fibroids **High-Yield:** Fibroids are monoclonal tumors arising from a single smooth muscle cell of the myometrium, not polyclonal proliferations. **Clinical Pearl:** The increased expression of estrogen and progesterone receptors in fibroid tissue (compared to normal myometrium) explains why fibroids grow during reproductive years and regress after menopause. **Key Point:** Fibroids are highly vascularized lesions with increased angiogenesis driven by growth factors: - VEGF (Vascular Endothelial Growth Factor) - FGF (Fibroblast Growth Factor) - TGF-β (Transforming Growth Factor-Beta) This explains their rich blood supply and the potential for heavy bleeding. ### Why Malignant Transformation Does NOT Occur | Feature | Fibroid (Leiomyoma) | Leiomyosarcoma | |---------|-------------------|----------------| | **Origin** | Benign smooth muscle tumor | Malignant smooth muscle tumor (de novo, not from fibroid) | | **Transformation risk** | 0.1-0.3% (extremely rare) | N/A | | **Presentation** | Slow growth, stable size | Rapid growth, aggressive course | | **Prognosis** | Excellent | Poor | **Warning:** Leiomyosarcomas arise de novo from myometrial smooth muscle, NOT from malignant transformation of pre-existing fibroids. The risk of a fibroid becoming malignant is <0.3%, not 15-20%. **Mnemonic:** **BENIGN** — Fibroids are Benign, monoclonal, Estrogen-dependent, Never transform, Increase with age, Growth factor-driven, Non-malignant.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.